Sunbelt Securities Inc. Increases Holdings in Elevance Health, Inc. $ELV

Sunbelt Securities Inc. increased its position in Elevance Health, Inc. (NYSE:ELV) by 42,311.1% during the first quarter, HoldingsChannel.com reports. The fund owned 3,817 shares of the company’s stock after acquiring an additional 3,808 shares during the quarter. Sunbelt Securities Inc.’s holdings in Elevance Health were worth $1,117,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ELV. Amundi raised its holdings in Elevance Health by 145.7% during the first quarter. Amundi now owns 2,693,664 shares of the company’s stock worth $788,570,000 after purchasing an additional 1,597,497 shares during the last quarter. Quantinno Capital Management LP boosted its position in Elevance Health by 144.0% during the first quarter. Quantinno Capital Management LP now owns 196,369 shares of the company’s stock worth $57,487,000 after purchasing an additional 115,886 shares in the last quarter. Hound Partners LLC acquired a new stake in Elevance Health in the first quarter valued at $1,152,000. Orbimed Advisors LLC grew its holdings in Elevance Health by 15.7% in the first quarter. Orbimed Advisors LLC now owns 114,700 shares of the company’s stock valued at $33,578,000 after purchasing an additional 15,600 shares during the last quarter. Finally, Intelligence Driven Advisers LLC purchased a new position in shares of Elevance Health in the first quarter valued at $208,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ELV. Guggenheim lifted their price target on Elevance Health from $399.00 to $455.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Jefferies Financial Group dropped their target price on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a report on Monday, April 20th. The Goldman Sachs Group restated a “neutral” rating and set a $395.00 target price on shares of Elevance Health in a research report on Thursday, July 16th. UBS Group lifted their target price on shares of Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Finally, Robert W. Baird increased their price target on shares of Elevance Health from $331.00 to $393.00 and gave the company a “neutral” rating in a research report on Thursday, July 16th. Fifteen analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $440.90.

Elevance Health Stock Down 0.1%

Shares of NYSE:ELV opened at $375.71 on Friday. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.68. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $436.24. The stock’s fifty day simple moving average is $397.38 and its 200-day simple moving average is $356.68. The company has a market capitalization of $81.48 billion, a P/E ratio of 16.70, a P/E/G ratio of 2.16 and a beta of 0.67.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 EPS for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. The business had revenue of $49.83 billion for the quarter, compared to analyst estimates of $48.88 billion. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The business’s revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter last year, the company earned $8.84 earnings per share. As a group, equities research analysts forecast that Elevance Health, Inc. will post 27.04 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Thursday, September 10th will be issued a dividend of $1.72 per share. The ex-dividend date is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. Elevance Health’s payout ratio is 30.58%.

Insider Activity at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the transaction, the director owned 10,734 shares of the company’s stock, valued at $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.34% of the stock is currently owned by company insiders.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Insider buying and investor support are improving sentiment. The company was named a “Pick of the Week” by Smart Insider after its CEO and chairman purchased shares, while a separate analysis said investor favor is strengthening ELV’s rebound. Such purchases can signal management confidence that the stock is undervalued. Elevance Health Pick of the Week at Smart Insider Following CEO, Chairman Share Purchases Investors’ Favour Strengthens Elevance Health’s Rebound
• Positive Sentiment: UnitedHealth Group’s results provide a favorable industry read-through. Improved margins, a lower medical-cost ratio and raised earnings guidance at UnitedHealth suggest that health insurers may be gaining better control over medical costs, potentially supporting expectations for an Elevance turnaround. UnitedHealth Just Gave Wall Street a Clearer Turnaround Signal
• Positive Sentiment: Long-term earnings forecasts were broadly raised. Zacks increased its FY2026 EPS estimate to $27.06, FY2027 to $28.83 and FY2028 to $32.49, above its previous forecasts and roughly consistent with or above the current-year consensus of $27.04.
• Neutral Sentiment: Recent trading has lagged peers. ELV underperformed competitors in the latest reported session, indicating that investors remain selective despite the broader recovery narrative. Elevance Health Inc. stock underperforms Wednesday when compared to competitors
• Negative Sentiment: Near-term earnings expectations were reduced. Zacks cut Q3 2026 EPS to $4.60 from $5.10 and Q4 EPS to $2.43 from $2.95, raising concerns about medical-cost pressure and near-term profitability.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.